We analyzed peripheral blood samples from one patient with relapsed/refractory MCL and three treatment-naïve patients (table S4) participating in an ongoing clinical trial (NCT04855695), assessing the combined effects of acalabrutinib, venetoclax, and obinutuzumab (AVO), which target BTK, BCL2, and CD20, respectively (56). Here, BTK is linked to mantle cell lymphoma.